Extract Standardization: DER, Markers & the Ratio Trap

Key takeaways

• A ratio like "10:1" and a marker like "5%" answer different questions, and neither replaces the other. The drug-extract ratio (DER) describes how much raw plant went into a unit of extract; the marker figure describes how much of a named constituent is in it. A defensible specification carries both, plus the assay method, plus the carrier.
• "10:1" alone says nothing about potency. DER is a concentration statement, not an activity statement. A native 10:1 extract of a marker-poor plant part, or a 10:1 figure quietly measured after carrier addition, can be weaker than a 4:1 grade — the ratio is only meaningful once you know whether it is native or adjusted and what marker sits underneath it.
• Markers are not all "active." Regulators distinguish active markers (contribute to the effect), analytical markers (used only to identify and quantify), and negative markers (undesirable constituents to be limited). A COA that names a percentage but not which kind of marker — and by which method — is telling you very little.
• Carriers and flow agents dilute the native extract and can inflate an apparent ratio. Maltodextrin, starch and silica add mass without adding actives. Adding carrier to a native extract raises the total finished weight, so the "drug-to-finished-extract" ratio can look bigger while the true native concentration falls. The percentage of native extract and excipient must be declared.
• Arovela is evaluated on documented lot control, not invented credentials. The relevant Arovela systems are ISO 22000, ISO 9001 and ISO 27001; organic, GMP or pharmacopoeial-grade status is a buyer-side requirement unless separately evidenced, and Arovela serves EU and Ukraine markets from Turkey.

Introduction

Few phrases cause more silent losses in botanical procurement than "standardized extract." The word implies rigour, but it is used loosely across the trade to mean at least three different things — a concentration ratio, a percentage of a named marker, or a full-spectrum extract held to a characteristic profile. Two powders can both be described as "standardized 10:1" or "standardized to 5%" and yet differ in what was measured, how it was measured, and whether the number describes native extract at all. The gap between what a buyer assumes and what the supplier actually committed to is exactly where price is lost and disputes are won or lost.

This guide is written for procurement, QA and regulatory staff at supplement brands, contract manufacturers and ingredient distributors buying bulk botanical extracts. It separates the three standardization approaches that buyers routinely conflate, explains why a ratio and a marker are not interchangeable, shows how carriers and excipients inflate an apparent ratio, and sets out the assay and RFQ language that pins a specification down. It builds on two adjacent Arovela case studies where these exact mechanics decide authenticity — the guides on grape seed extract OPC standardization and pomegranate peel punicalagin authenticity — and on the broader controls in sourcing botanical extracts for EU brands and reading a botanical COA.

The three things "standardized" can mean

Before comparing any two offers, establish which of these three claims is on the table. They are not competing grades of the same idea; they answer different questions and are often combined.

1. Drug-extract ratio (DER): a concentration statement

The drug-extract ratio — written as "10:1", "4:1" and so on — states how much dried raw plant material (the "drug", in the pharmacognosy sense) was used to produce one unit of extract. A 10:1 dry extract means, on average, roughly ten parts of starting herb yielded one part of extract. It is a concentration statement about process yield, not a statement about how much of any active compound is present.

The critical distinction the trade blurs is native versus adjusted:

• Native (genuine) DER — described by the European Medicines Agency's herbal committee as the DER genuine — is the ratio of herbal starting material to the native extract only, before any excipient is added. This is the honest number: it reflects real concentration.
• Adjusted DER applies when excipients (carriers, diluents) are added to bring a variable extract onto a fixed marker target. Once carrier is in the powder, the ratio of raw material to finished extract is no longer the native ratio.

This is why "10:1" on its own is close to meaningless for potency. First, it does not name the marker, so a 10:1 extract of a marker-poor plant part can carry less active than a lower-ratio extract of a rich part. Second, if the "10:1" is quoted against finished (adjusted) extract rather than native extract, carrier has diluted it — the raw-to-native concentration is lower than the headline implies. As the peer-reviewed review of plant-to-extract ratios puts it, "the extract ratio alone doesn't tell consumers or practitioners the true potency of the product," and any carrier or diluent must be taken into account when judging whether two extracts are equivalent (Frontiers in Pharmacology / PMC, 2022).

2. Marker / assay standardization: a content statement

Marker standardization fixes the extract to a percentage of a named constituent — "5% withanolides", "40% ellagic acid", "95% total polyphenols". Here the extract is manufactured and released so that each batch meets a defined assay value for that marker, verified analytically and recorded on the COA.

The essential move most buyers skip is asking which kind of marker is being quoted. Regulatory and pharmacognosy literature (the EMEA/EMA framework, echoed by WHO-aligned quality guidance) classifies marker constituents into distinct roles:

• Active markers — constituents that contribute to the therapeutic or functional activity. Standardizing to an active marker is the strongest kind of content claim.
• Analytical markers — constituents chosen purely because they are convenient to identify and quantify; they may have no clinical activity themselves and serve "solely for analytical purposes". A percentage of an analytical marker confirms identity and consistency but does not prove potency.
• Negative markers — undesirable or allergenic/toxic constituents that standardization aims to limit or remove. Eliminating a negative marker is itself a recognised form of standardization.

So "standardized to 5%" is ambiguous until you know whether that 5% is an active marker (meaningful for effect), an analytical marker (meaningful for identity only), or whether a negative marker is being controlled in parallel. The distinction is not academic — the ECA/GMP guidance on herbal reference standards is built entirely around telling active and analytical markers apart, because you validate and interpret them differently.

3. Full-spectrum / quantified extracts: a profile statement

A full-spectrum extract is positioned as retaining the plant's whole native constituent profile rather than being concentrated toward a single marker. In the EMA taxonomy this lands closest to the categories of "quantified" and "other" extracts:

• Standardised extracts (EMA sense): the known, adjusted constituents are understood to fully account for the proven activity — e.g. sennosides in senna, silymarin in milk thistle, gingerols in ginger.
• Quantified extracts: the identified constituents partly but not fully account for activity; they are quantified and held to a range, but the whole extract still matters.
• Other extracts: defined essentially by their process and DER, with no constituents of accepted therapeutic relevance to quantify.

For a buyer, "full-spectrum" is a legitimate and often desirable choice — but it shifts the burden of proof onto the DER, the extraction process, and a characteristic fingerprint, because there is no single dominant marker doing the identity work. A full-spectrum claim with no DER, no defined process and no fingerprint is unfalsifiable.

Values and forms above are illustrative ("e.g."); the binding statement is whatever the supplier commits to on the COA against a named method and reference standard. For the underlying logic in a real category, see the grape seed OPC guide.

Why a ratio and a marker are not interchangeable

The single most common purchasing error is treating a DER and a marker percentage as substitutes — accepting "10:1" instead of a marker, or "5%" instead of a ratio. They measure orthogonal things:

• DER without a marker tells you concentration but not what was concentrated. Ten kilos of a low-marker leaf still make a "10:1" extract.
• Marker without a DER tells you the assay value of one constituent but not how the extract was made or how much carrier sits underneath it — a "5%" powder could be a native extract or a low-grade extract cut with carrier and re-standardized up to 5% by spiking (see below).

A defensible specification therefore always carries both, tied together: a native DER and a named marker at a stated percentage and the assay method and the carrier/excipient declaration. Any one of those alone is half a specification. This is precisely the discipline the pomegranate peel guide applies when it separates the identity marker (punicalagins) from the potency marker (ellagic acid) and reconciles both against the DER.

Carriers, excipients and flow agents: how an apparent ratio inflates

Bulk extracts are rarely pure native extract. To make a hygroscopic, sticky native extract into a free-flowing, dosable powder — and to hit a fixed marker target batch after batch — manufacturers add:

• Carriers / diluents such as maltodextrin, dextrose, gum arabic or starch, which add bulk during spray-drying and standardize the marker percentage downward to a target.
• Flow / anti-caking agents such as silicon dioxide, and absorbents used to fix liquid or oleoresin extracts onto a powder.

These excipients contribute mass but no actives, and that is where the ratio games live. The plant-to-extract-ratio literature gives the mechanism plainly: if roughly four kilos of raw material yield one kilo of native extract (a native 4:1), then adding one kilo of carrier per kilo of native extract doubles the finished mass — so the same native material can now be presented against a larger finished quantity, inflating the apparent amount of "extract" without adding a gram of active compound (Frontiers in Pharmacology / PMC, 2022). A "10:1 with 30% maltodextrin" carries the same headline ratio as a carrier-free 10:1 but a materially lower effective concentration.

The control is the EMA-style declaration: the COA and technical data sheet should state the percentage of native (genuine) extract, the native DER, and the percentage and identity of every excipient. Without the native-extract percentage, an extract-equivalent calculation is impossible and two "identical" ratios cannot be compared. A carrier that appears only as an unexplained gap between a low marker figure and a high DER — with high loss-on-drying or ash — is a flag, exactly as flagged in the pomegranate case.

Specification limit versus typical value

A recurring source of dispute is confusing two numbers that look alike on a COA:

• A specification limit is a binding release gate — the minimum (or maximum, or range) every batch must meet before it can ship, e.g. "withanolides ≥ 5%". It is a commitment.
• A typical value is descriptive marketing — "typically 8–10%" — with no contractual force. A batch that assays at 4% has failed a ≥5% specification but is perfectly consistent with a "typically 8–10%" brochure.

Best practice, and cGMP expectation, is that a COA reports the actual numeric result against the specification point or range — "conforms" or "pass" is not a valid result. When you write your RFQ, convert every "typically" into a specification limit with a unit, a method and a decision rule; otherwise you are buying prose, not a spec.

Assay methods: why the method must be named

A marker percentage is only interpretable alongside the analytical method that produced it, because different methods measure different things and have very different selectivity.

HPLC (and LC-MS): specific, per-compound

Reverse-phase HPLC with UV/PDA detection resolves and quantifies individual named constituents and produces a pattern — a fingerprint — that supports identity as well as content. It is the method of choice when the marker is a defined molecule (a specific withanolide, ellagic acid, a named procyanidin). Coupled to mass spectrometry (LC-MS/HRMS) it can confirm ambiguous peaks and detect species substitution at the extract level.

UV / spectrophotometric (Folin-Ciocalteu, DMAC): class totals, not identity

UV-visible assays measure a class of compounds at a wavelength or via a colour reaction — total polyphenols by Folin-Ciocalteu, total proanthocyanidins by DMAC, total flavonoids, and so on. They are fast, cheap and reproducible, but non-specific: they respond to any compound in the class, including phenolics from a different, cheaper plant or an added isolate. UV methods are screens for total load, never identity or authenticity tests — a point the grape seed guide makes at length, since a colorimetric "95%" can pass adulterated material.

The buyer rule is simple: a percentage with no method is uninterpretable. "95%" by Folin-Ciocalteu (a broad class total) and "95%" by HPLC against a named reference standard are not the same claim, and a specification must name the technique, the reference standard and the wavelength/conditions.

How standardization games work

Because a marker figure can be met without honest extract behind it, standardization is a well-documented target for economically motivated adulteration. The forensic literature on botanical ingredients describes the recurring moves:

• Spiking with an isolated marker. An understrength extract is "fortified" with a pure or purified marker compound — often cheaply synthesised or isolated — so the assay peak reaches the target. Analysts note this is one of the hardest frauds to catch, because the spiked molecule is chemically identical to the genuine marker (Journal of Natural Products, 2023).
• Cheaper plant source of the same marker. The marker is supplied from a lower-cost botanical — a different, cheaper plant, or a cheaper part of the same plant (e.g. aerial parts standing in for root) — that shares the constituent. This is the mechanism behind grape seed cut with peanut-skin proanthocyanidins and pomegranate "standardized to ellagic acid" sourced from non-pomegranate plants; both are dissected in the grape seed and pomegranate peel guides.
• Carrier dilution then re-standardization. Native extract is over-diluted with maltodextrin and then the marker % is "recovered" by spiking, so a weak, carrier-heavy powder presents an on-target number.

The defence is layered and the same in every category: quantify the marker by a specific method (HPLC, not only UV), require an identity fingerprint against authentic reference material, reconcile the marker against the native DER and carrier declaration, and — where a cheaper same-marker source is plausible — demand a botanical-origin test the colorimetric number cannot fake. General red flags are collected in the COA red-flags guide.

RFQ and COA language that pins it down

Vague RFQs invite every ambiguity above. Direct wording closes them. The table maps each field to what it prevents; the clause is adaptable text.

"Supplier shall provide, per lot, a COA stating: the herbal starting material, plant part, and the native (genuine) drug-extract ratio (DER); the standardization marker(s) by name, the assay percentage as a specification limit (not a typical value), the analytical method (e.g. HPLC-UV against a named reference standard; UV/colorimetric methods identified as class totals), and whether each marker is active or analytical; the percentage of native extract and the identity and percentage of every carrier, diluent and flow agent (e.g. maltodextrin, silicon dioxide); an HPLC/HPTLC identity fingerprint consistent with authentic material; and loss on drying, ash, residual solvents to ICH Q3C limits, heavy metals and microbiology. Each result shall include method, limit, unit, sample date, lot number and laboratory accreditation."

This single paragraph forces the three claims apart — ratio, marker, profile — and ties them back together with the carrier declaration and identity fingerprint that headline numbers alone can never supply. Confirm scope on the Arovela certifications page before you finalise acceptance limits.

Where Arovela's ISO systems fit — and where they do not

None of this is replaced by a certificate. Arovela operates ISO 22000 (food-safety management), ISO 9001 (quality management) and ISO 27001 (protecting the confidentiality of buyer specifications). Those systems support disciplined lot control, documentation and traceability — but a specific DER, marker percentage, fingerprint or contaminant result must come from the analytical work on the lot, ideally from an accredited laboratory. Arovela does not hold organic, GMP or pharmacopoeial-grade status unless separately evidenced, and supplies Turkey-origin material into EU and Ukraine markets only. The honest position is the strong one: the ISO systems make the paperwork trustworthy; the assay makes the claim true.

Frequently asked questions

Does a "10:1" extract mean it is stronger than a "4:1"?

Not necessarily. DER is a concentration statement about process yield, not a potency statement. A 10:1 extract of a marker-poor plant part can carry less active than a 4:1 extract of a rich part, and a "10:1" quoted against finished (adjusted) extract may already be diluted with carrier, so the true native concentration is lower than the number implies. Compare a native DER together with a named marker percentage and the carrier declaration — never the ratio alone.

What is the difference between an active marker and an analytical marker?

An active marker contributes to the extract's functional or therapeutic effect, so a percentage of it is a meaningful potency proxy. An analytical marker is chosen only because it is convenient to identify and quantify and may have no activity itself, so its percentage confirms identity and batch consistency but not potency. Negative markers are undesirable constituents that standardization limits or removes. A COA that states a percentage without saying which kind of marker it is — and by which method — is telling you very little.

How do carriers like maltodextrin affect the extract ratio?

Carriers and flow agents (maltodextrin, starch, silica) add mass but no active compounds. Adding carrier to a native extract increases the finished weight, which can make a "drug-to-finished-extract" ratio look larger while the true native concentration falls. This is why the specification must state the percentage of native extract and the identity and percentage of every excipient — without those, two extracts with the same headline ratio are not comparable, and an apparently high ratio can conceal a heavily diluted powder.

Why must the assay method be named on the COA?

Because different methods measure different things. HPLC (or LC-MS) quantifies specific named constituents and supports an identity fingerprint; UV/colorimetric methods such as Folin-Ciocalteu or DMAC measure a whole class of compounds and respond to any member of that class, including phenolics from a cheaper plant or an added isolate. A "95%" by a non-specific UV method and a "95%" by HPLC against a reference standard are different claims. Requiring the method, reference standard and conditions is what makes a marker percentage interpretable and hard to fake.

Source standardized extracts with a defensible specification

If your team is buying bulk botanical extracts from Turkey for the EU or Ukraine, Arovela can support lot-specific COA review, DER, marker and identity documentation, and export planning within its ISO 22000, ISO 9001 and ISO 27001 systems — without claiming certifications it does not hold. Start with a technical quote request, compare wholesale supply options, or review Arovela certifications before you finalise your ratio, marker and carrier limits.